f****o
发帖数: 2770 | 1 Erlotinib (Tarceva)
bevacizumab (Avastin), (in combination with paclitaxel and carboplatin)
Crizotinib if EML4-ALK fusion oncogene |
|
K******S
发帖数: 10109 | 2 that's quick. EML4-ALK fusion was discovered around 2007. It only takes 4
years to have a commercial drug. |
|
l*****1
发帖数: 8 | 3 http://www.ncbi.nlm.nih.gov/pubmed?term=20551945
Nature Reviews Clinical Oncology 7, 401-414 (July 2010) | doi:10.1038/
nrclinonc.2010.64
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Filip Janku, David J. Stewart & Razelle Kurzrock
Abstract
Treatment outcomes in advanced or metastatic non-small-cell lung cancer (
NSCLC) remain unsatisfactory, with low long-term survival rates. Palliative
chemotherapy offers a median survival not exceeding 1 year. To date, various
comb... 阅读全帖 |
|
yf
发帖数: 272 | 4 要不要试一下做个eml4-alk mutation 的检查，虽然只有少数患者有这个基因突变，但
是如果有就可以用crizotinib，效果很好。（Kwak et al. Nemj 2010)你可以google一
下。现在正在做临床试验。 |
|
I****a
发帖数: 407 | 5 Does your relative have EML4/ALK translocation?
You need provide more information. |
|
I****a
发帖数: 407 | 6 1. On the contrary, BRAF inhibitor is used for mutated BARFV600E
2. EGFR monocloncal antibody is only useful in KRAS wild type patient
because mutated KRAS does not need upstream EGFR signaling to activate
downstream targets.
3. EGFR tyrosine kinase inhibitor is good for EGFR mutated patient
4. ALK TKI is good for ALK-EML4 translocation patient. |
|
yf
发帖数: 272 | 7 It's unfortunate that such a young man is facing serious cancer problem. As
a oncologist, I am here to give my two cents though I haven't seen the
patient yet.
First: What is the type of lung cancer and what stage? This is very
important. If patient has stage four squamous cell carcinoma. There are
limited chemotherapy options. The chemo agent that can be used are Cisplatin
or carboplatin in combination with paclitaxol or Gemcitabine. Some old
regimens such as vinorelbine can be used too. Second... 阅读全帖 |
|
